ABSTRACT
Abstract INTRODUCTION: Although supervised doses are essential for reducing leprosy treatment failure, the impact of specific drug interactions has rarely been assessed. This study aimed to estimate the risk of leprosy treatment suspension in patients receiving polypharmacy. METHODS We performed this case-control study in which the primary outcome was defined as the need to discontinue multibacillary leprosy treatment for at least one supervised dose, and the main risk factor was the detection of polypharmacy. Multivariate analysis by logistic regression was used for calculating odds ratio (OR). RESULTS: This study included 103 patients, of whom 43 needed to discontinue leprosy treatment (hemolysis = 26, hepatitis = 2, hemolysis associated with hepatitis = 6, and suspected treatment resistance = 9) and the rest did not. The severity of drug interactions had no effect on treatment discontinuation. Patients who used five or more drugs in addition to leprosy treatment had almost a 4-fold greater risk of treatment suspension (OR, 3.88; 95% confidence interval: 1.79-9.12; p < 0.001). The number of drugs used also positively influenced the occurrence of hemolysis (p < 0.001). No patient presented evidence of molecular resistance to rifampicin, dapsone, or ofloxacin treatment, as evidenced by genetic sequencing detection of rpoB, folp1, and gyrA mutations. CONCLUSIONS: Polypharmacy has deleterious effects on the already difficult-to-adhere-to treatment of leprosy and polypharmacy induces hemolysis. Additional measures must be taken to avoid the undesirable effects of inadequate polypharmacy.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Aged , Aged, 80 and over , Young Adult , Polypharmacy , Drug Interactions , Leprostatic Agents/administration & dosage , Leprosy/drug therapy , Case-Control Studies , Risk Factors , Leprostatic Agents/adverse effects , Middle AgedABSTRACT
Abstract: BACKGROUND: The Clinical Trial for Uniform Multidrug Therapy for Leprosy Patients in Brazil (U-MDT/CT-BR), designed to evaluate the effectiveness of a six-months regimen, assessed the adverse effects caused by the drugs. OBJECTIVE: Describe adverse effects due to MDT in U-MDT/CT-BR, comparing the uniform regimen (U-MDT) to the current WHO regimen (R-MDT). Patients and methods: After operational classification, patients were randomly allocated to the study groups. U-MDT PB and U-MDT MB groups, received the U-MDT regimen, six doses of MB-MDT (rifampicin, dapsone and clofazimine). R-MDT PB and R-MDT MB groups, received the WHO regimens: six doses (rifampicin and dapsone) for PB and 12 doses (rifampicin, dapsone and clofazimine) for MB. During treatment, patients returned monthly for clinical and laboratorial evaluation. Patients with single lesion were not included in this trial. RESULTS: Skin pigmentation (21.7%) and xerosis (16.9%) were the most frequent complaints among 753 patients. Laboratory exams showed hemoglobin concentration lower than 10g/dL in 23.3% of the patients, glutamic oxaloacetic transaminase (GOT) above 40U/L in 29.5% and glutamic pyruvic transaminase (GPT) above 40U/L in 28.5%. Twenty-four patients (3.2%) stopped dapsone intake due to adverse effects, of whom 16.6% due to severe anemia. One case of sulfone syndrome was reported. STUDY LIMITATIONS: Loss of some monthly laboratory sample collection. CONCLUSIONS: There was no statistical difference regarding adverse effects in the R-MDT and U-MDT groups but anemia was greater in patients from R-MDT/MB group, therefore adverse effects do not represent a constraint to recommend the six-month uniform regimen of treatment for all leprosy patients.
Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Young Adult , Rifampin/adverse effects , Clofazimine/adverse effects , Dapsone/adverse effects , Leprostatic Agents/adverse effects , Rifampin/administration & dosage , Brazil , Hemoglobins/analysis , Risk Factors , Treatment Outcome , Clofazimine/administration & dosage , Dapsone/administration & dosage , Drug Therapy, Combination/adverse effects , Anemia/chemically induced , Anemia/blood , Leprostatic Agents/administration & dosage , Leprosy/complications , Leprosy/drug therapy , Leprosy/bloodABSTRACT
Abstract INTRODUCTION: The occurrence of leprosy reactions, a common event during treatment, may be mostly related to the action of multidrug therapy on Mycobacterium leprae. The clinical and laboratory monitoring of patients with reactions is important, since collecting data that assists in predicting the risk of reactions may help to prevent disability. METHODS: This was a sectional study, in order to correlate clinical and laboratory diagnosis with the number of reactions during treatment. Spearman's correlation was used to verify the degree of association between the assessed variables. RESULTS: This study was conducted with 211 patients with leprosy reactions during treatment of M. leprae. The borderline tuberculoid group was the most prevalent clinical form (74/211; 35.1%) and the type one reaction showed the highest frequency (136/211; 64.5%). It was observed that 73.5% (155/211) of reactions occurred within 3 months of the initiation of multidrug therapy. The diagnostic values, including the bacterial indices (BIs) of dermal smears (r = 0.21, p < 0.05) and skin biopsies (r = 0.20; p < 0.05), showed a positive correlation with the number of reactions during treatment. CONCLUSIONS: This research showed a positive correlation between bacillary load markers and the number of leprosy reactions. This study provided scientific support to future research aiming to elucidate the influence of antigenic load on the number of leprosy reactions during treatment.
Subject(s)
Humans , Leprostatic Agents/administration & dosage , Leprosy/drug therapy , Antibodies, Bacterial/blood , Mycobacterium leprae/drug effects , Antigens, Bacterial/blood , Time Factors , Cross-Sectional Studies , Statistics, Nonparametric , Drug Therapy, Combination , Leprostatic Agents/adverse effects , Leprosy/microbiology , Mycobacterium leprae/immunologyABSTRACT
Introduction: There is no information in Colombia on Mycobacterium leprae primary and secondary drug resistance in regards to the WHO-multidrug therapy regime. On the other hand, public health authorities around the world have issued various recommendations, one of which prompts for the immediate organization of resistance surveillance through simple molecular methods. Objective: To determine the prevalence of Mycobacterium leprae drug resistance to rifampicin, ofloxacin and dapsone in untreated and previously treated patients at the Centro Dermatológico Federico Lleras Acosta during the 1985-2004 period. Materials and methods: We conducted a retrospective study which included multibacillary patient biopsies through elective sampling: 381 of them from new patients and 560 from previously treated patients. Using a microtome, we obtained six slides from each skin biopsy preserved in paraffin, and we extracted M. leprae DNA. We amplified three molecular targets through PCR and obtained the patterns of drug resistance to dapsone, rifampicin and ofloxacin by reverse hybridization. Finally, we collected epidemiological, clinical and demographical data for analyses. Results: From 941 samples under study, 4.14% of them were resistant to one or more drugs, and 5.77 and 3.04% had resistant genotypes in new and previously treated patients, respectively. Total resistance for each drug was 0.43% for dapsone, 3.19% for rifampicin and 1.17% for ofloxacin. We found statistically significant differences for rifampicin and for the total population when comparing the results from untreated versus previously treated patients. Two thirds of the resistant samples were resistant to rifampicin alone or combined. Conclusions: The standard multidrug therapy schemes continue being effective for leprosy cases; however, it is necessary to guarantee adherence and regularity. Surveillance to drug resistance in new and previously treated leprosy cases should be established.
Introducción. Colombia no dispone de información sobre farmacorresistencia primaria y secundaria de Mycobacterium leprae al esquema de terapia múltiple de la Organización Mundial de la Salud (OMS) y las autoridades de salud pública del mundo han emitido varias recomendaciones, entre las cuales está organizar de inmediato la vigilancia a la resistencia empleando métodos moleculares simples. Objetivo. Determinar la prevalencia de la resistencia de M. leprae a rifampicina, ofloxacina y dapsona en pacientes del Centro Dermatológico Federico Lleras Acosta con tratamiento previo y sin él durante el período de 1985 a 2004. Materiales y métodos. Se realizó un estudio retrospectivo. Mediante muestreo electivo se incluyeron biopsias de pacientes multibacilares: 381 de pacientes nuevos y 560 de pacientes previamente tratados. Se obtuvieron con micrótomo seis cortes de cada biopsia de piel incluida en parafina, y se realizó la extracción de ADN de M. leprae. Se llevó a cabo la amplificación de tres blancos moleculares mediante PCR y se obtuvieron los patrones de resistencia a los medicamentos dapsona, rifampicina y ofloxacina por hibridación inversa. Se recolectaron datos epidemiológicos, clínicos y demográficos para llevar a cabo los análisis. Resultados. De las 941 muestras estudiadas, 4,14 % era resistente a uno o más fármacos, y se detectaron 5,77 y 3,04 % con genotipos resistentes en pacientes nuevos y previamente tratados, respectivamente. La resistencia total para cada fármaco fue de 0,43 % a dapsona, 3,19 % a rifampicina y 1,17 % a ofloxacina. Se encontró una diferencia estadísticamente significativa para rifampicina y para la población total al comparar los resultados de los pacientes no tratados con los de los pacientes tratados previamente. Dos tercios de las muestras resistentes lo fueron a rifampicina sola o combinada. Conclusiones. Los esquemas de terapia múltiple estándar siguen siendo efectivos para los casos de lepra; sin embargo, es necesario garantizar el cumplimiento y la regularidad y establecer la vigilancia de la farmacorresistencia en pacientes nuevos y previamente tratados.
Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Young Adult , Drug Resistance, Multiple, Bacterial , Leprostatic Agents/pharmacology , Leprosy, Multibacillary/microbiology , Mycobacterium leprae/drug effects , Biopsy , Bacterial Proteins/genetics , Colombia/epidemiology , DNA, Bacterial/genetics , Drug Therapy, Combination , Dapsone/pharmacology , Drug Resistance, Bacterial/genetics , Drug Resistance, Multiple, Bacterial/genetics , Genotype , Leprostatic Agents/administration & dosage , Leprostatic Agents/therapeutic use , Leprosy, Multibacillary/epidemiology , Leprosy, Multibacillary/pathology , Mycobacterium leprae/genetics , Mycobacterium leprae/isolation & purification , Ofloxacin/pharmacology , Polymerase Chain Reaction , Retrospective Studies , Rifampin/pharmacologyABSTRACT
BACKGROUND: Leprosy can have its course interrupted by type 1 and 2 reactional episodes, the last named of erythema nodosum leprosum (ENL). Thalidomide has been the medication of choice for the control of ENL episodes since 1965. OBJECTIVES: These episodes can repeat and cause damages to the patient. In order to prevent these episodes, an extra dose of 100 mg/day thalidomide was used during six months, followed by a follow-up period of six more months after thalidomide discontinuation. METHODS: We included 42 patients with multibacillary (MB) leprosy who had episodes of ENL. They were male and female patients aged between 18 and 84 years. RESULTS: Of the 42 patients, 39 (92.85%) had the lepromatous form and three (7.15%) had the borderline form. We found that 100% of patients had no reactional episode during the use of the drug. During the follow-up period after thalidomide discontinuation, 33 (78.57%) patients had no reactional episode and nine (21.43%), all of them with the lepromatous form, had mild episodes, which were controlled using non-steroidal anti-inflammatory. There were no thalidomide-related side effects. CONCLUSION: A maintenance dose of 100 mg/day of thalidomide showed to be effective to prevent repeated type 2 reactional episodes of ENL. .
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Erythema Nodosum/drug therapy , Leprostatic Agents/administration & dosage , Leprosy, Borderline/drug therapy , Leprosy, Lepromatous/drug therapy , Thalidomide/administration & dosage , Dose-Response Relationship, Drug , Erythema Nodosum/prevention & control , Follow-Up Studies , Leprosy, Borderline/prevention & control , Leprosy, Lepromatous/prevention & control , Severity of Illness Index , Sex Factors , Treatment OutcomeABSTRACT
BACKGROUND: After the introduction of the multidrug therapy, there was a decline in the coefficients of prevalence and detection of new cases of leprosy. However, the records of drug resistance and relapses are threatening factors in leprosy control. Hence, new alternative schemes and monitoring of adverse effects to avoid treatment abandonment are important considerations. OBJECTIVE: Describe the side effects of a multidrug regimen containing minocycline, ofloxacin, and clofazimine in multibacillary leprosy patients. METHODS: We conducted a prospective, descriptive, and observational study with multibacillary patients, including cases of intolerance to standard MDT and relapses. The study was carried out at Fundação Alfredo da Matta (Alfredo da Matta Foundation), in Manaus, Amazonas, from April 2010 to January 2012. The patients received alternative therapy, which consisted of daily self-administered doses of 100mg of minocycline, 400 mg of ofloxacin, and 50mg of clofazimine and a supervised monthly dose of 300mg of clofazimine for six months, followed by eighteen months of daily doses of ofloxacin 400mg, clofazimine 50mg, and a supervised monthly dose of clofazimine 300mg. Results: Twenty-one cases were included. Mild and transitory side effects occurred in 33.3% of patients. Of the total episodes, 45.9% were attributed to ofloxacin and they included abdominal pain, nausea, vomiting, headache, and insomnia; 21.6% were due to clofazimine, with 100% of patients presenting skin pigmentation. The mean time for the development of adverse effects after beginning the therapy was 15.2 days. CONCLUSION: All patients tolerated the drugs well, and compliance was satisfactory, with no serious events. Unlike other standard MDT studies ...
FUNDAMENTOS: Após introdução do esquema poliquimioterápico padrão, houve declínio nos coeficientes de prevalência e detecção de casos novos; entretanto, os registros de resistência medicamentosa e recidivas representam ameaça para o controle da hanseníase. Dessa forma, a proposição de novos esquemas alternativos e a necessidade de monitorar efeitos adversos são importantes para evitar o abandono do tratamento. OBJETIVO: Descrever efeitos adversos do esquema alternativo contendo clofazimina, ofloxacina e minociclina em pacientes com hanseníase multibacilar. MÉTODOS: Estudo prospectivo, descritivo e observacional de casos multibacilares, incluindo recidivas ou intolerância à poliquimioterapia padrão, realizado na Fundação Alfredo da Matta, Manaus, Amazonas, de abril de 2010 a janeiro de 2012. Os indivíduos receberam a terapia composta de doses diárias auto-administradas de 100mg de minociclina, 400mg de ofloxacina e 50mg de clofazimina e mensais supervisionadas de 300mg de clofazimina por seis meses, seguidas de 18 meses de doses diárias de ofloxacina 400mg, clofazimina 50 mg e supervisionadas mensais de clofazimina 300mg. Resultados: 21 pacientes foram incluídos. Efeitos adversos leves e transitórios foram observados em 33,3% dos pacientes; 45,9% foram atribuídos à ofloxacina, como dor abdominal, náuseas, vômitos, cefaléia e insônia; 21,6% foram associados à clofazimina, com relatos e observação em 100% dos pacientes de hiperpigmentação cutânea. O tempo médio de desenvolvimento das reações adversas a partir do início do esquema foi de 15,2 dias. ...
Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Clofazimine/adverse effects , Leprostatic Agents/administration & dosage , Leprosy, Multibacillary/drug therapy , Minocycline/adverse effects , Ofloxacin/adverse effects , Brazil , Clofazimine/administration & dosage , Drug Therapy, Combination/adverse effects , Drug Therapy, Combination/methods , Minocycline/administration & dosage , Ofloxacin/administration & dosage , Statistics, Nonparametric , Time Factors , Treatment OutcomeABSTRACT
Leprosy will continue to be a public health problem for several decades. The World Health Organization (WHO) recommends that, for treatment purposes, leprosy cases be classified as either paucibacillary or multibacillary (MB). A uniform leprosy treatment regimen would simplify treatment and halve the treatment duration for MB patients. The clinical trial for uniform multidrug therapy (U-MDT) for leprosy patients (LPs) in Brazil is a randomised, open-label clinical trial to evaluate if the effectiveness of U-MDT for leprosy equals the regular regimen, to determine the acceptability of the U-MDT regimen and to identify the prognostic factors. This paper details the clinical trial methodology and patient enrolment data. The study enrolled 858 patients at two centres and 78.4% of participants were classified as MB according to the WHO criteria. The main difficulty in evaluating a new leprosy treatment regimen is that no reliable data are available for the current treatment regimen. Relapse, reaction and impaired nerve function rates have never been systematically determined, although reaction and impaired nerve function are the two major causes of nerve damage that lead to impairments and disabilities in LPs. Our study was designed to overcome the need for reliable data about the current treatment and to compare its efficacy with that of a uniform regimen.
Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Clinical Protocols , Leprostatic Agents/administration & dosage , Leprosy, Multibacillary/drug therapy , Leprosy, Paucibacillary/drug therapy , Brazil , Drug Therapy, Combination/methods , Treatment OutcomeABSTRACT
This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs. This quantitative, prospective, nested study was developed at the Dona Libânia Dermatology Centre in Fortaleza, Brazil. Data were collected from November 2007-November 2008. During this period, 818 leprosy patients were diagnosed and began treatment. Forty patients with tuberculoid leprosy (TT) were selected. Twenty patients followed a standard therapy of dapsone and rifampicin and 20 were administered dapsone, rifampicin and clofazimine (U-MDT). Twenty patients with borderline lepromatous (BL) and lepromatous leprosy (LL) were also selected and treated with U-MDT. All of the subjects received six doses. With the exception of haemolytic anaemia, there was a low incidence of adverse effects in all the groups. We did not observe any differences in the incidence of haemolytic anaemia or other side effects across groups of patients with TT, BL or LL treated with U-MDT.
Subject(s)
Adolescent , Adult , Aged , Child , Humans , Middle Aged , Young Adult , Leprostatic Agents/administration & dosage , Leprosy, Lepromatous/drug therapy , Leprosy, Multibacillary/drug therapy , Leprosy, Tuberculoid/drug therapy , Clofazimine/administration & dosage , Clofazimine/adverse effects , Drug Therapy, Combination , Dapsone/administration & dosage , Dapsone/adverse effects , Leprostatic Agents/adverse effects , Prospective Studies , Rifampin/administration & dosage , Rifampin/adverse effectsABSTRACT
Despite the huge effort and massive advances toward the elimination of leprosy over the last two decades, the disease has proven stubborn; new case detection rates have stabilised over the last few years and leprosy remains endemic in a number of localised regions. The American Leprosy Missions and Infectious Disease Research Institute have undertaken a large research effort aimed at developing new tools and a vaccine to continue the push for leprosy elimination. In this paper, we outline our strategy for the integration of rapid diagnostic tests and lab-based assays to facilitate the detection of early or asymptomatic leprosy cases, as well as the efficient and focused implementation of chemoprophylaxis and immunisation to intervene in leprosy development and transmission.
Subject(s)
Humans , Bacterial Vaccines/therapeutic use , Leprostatic Agents/administration & dosage , Leprosy/prevention & control , Mycobacterium leprae/immunology , Vaccination , Contact Tracing , Leprosy/diagnosis , Leprosy/epidemiologyABSTRACT
Mucormycosis is an uncommon fungal infection caused by Mucorales. It frequently occurs in patients with neutropenia, diabetes, malignancy and on corticoid therapy. However, it is rare in patients with AIDS. Clinical disease can be manifested in several forms. The case reported illustrates the rare occurrence of chromoblastomycosis and mucormycosis in an immunosuppressed patient with multibacillary leprosy, under prolonged corticosteroid and thalidomide therapy to control leprosy type 2 reaction. Neutrophil dysfunction, thalidomide therapy and work activities are some of the risk factors in this case. Chromoblastomycosis was treated by surgical excision and mucormycosis with amphotericin B. Although the prognosis of mucormycosis is generally poor, in the reported case the patient recovered successfully. This case should alert dermatologists to possible opportunistic infections in immunosuppressed patients.
Mucormicose é uma infecção fúngica incomum causada por Mucorales. Ocorre frequentemente em pacientes com neutropenia, diabetes, corticoterapia e condições malignas. Porém, é rara em pacientes com AIDS. A doença pode apresentar-se em diferentes formas. Este caso ilustra a rara ocorrência de mucormicose e cromoblastomicose em um paciente com hanseníase multibacilar, que estava sendo tratado com prednisona e talidomida devido a eritema nodoso (reação hansênica tipo II). Disfunção de neutrófilos, uso de talidomida e atividades profissionais são alguns fatores de risco neste caso. A cromoblastomicose foi tratada por excisão cirúrgica e a mucormicose com anfotericina B. Embora o prognóstico da mucormicose seja ruim, neste caso o tratamento foi bem sucedido. Este caso alerta dermatologistas para a possibilidade de infecções oportunistas em pacientes imunossuprimidos.
Subject(s)
Adult , Humans , Male , Chromoblastomycosis/immunology , Immunocompromised Host/immunology , Leprosy, Multibacillary/drug therapy , Mucormycosis/immunology , Chromoblastomycosis/pathology , Glucocorticoids/administration & dosage , Glucocorticoids/immunology , Leprostatic Agents/administration & dosage , Leprostatic Agents/immunology , Mucormycosis/pathology , Prednisone/administration & dosage , Prednisone/immunology , Thalidomide/administration & dosage , Thalidomide/immunologySubject(s)
Aged , Humans , Male , Erythema Nodosum/drug therapy , Leprostatic Agents/administration & dosage , Leprosy, Lepromatous/drug therapy , Substance Withdrawal Syndrome/etiology , Thalidomide/administration & dosage , Erythema Nodosum/pathology , Leprosy, Lepromatous/pathology , Severity of Illness Index , Substance Withdrawal Syndrome/pathologyABSTRACT
A hanseníase é uma doença crônica que pode ter seu curso alterado por episódios reacionais do tipo 1 e do tipo 2 ou de eritema nodoso hansênico (ENH) . A talidomida é a medicação de eleição para controle do episódio de ENH desde 1965. No entanto, esses episódios podem se apresentar de forma repetitiva, com consequentes danos ao paciente. Com o intuito de se evitar esses episódios, após o controle dos mesmos com a dose tradicional, utilizou-se a dose de 100mg/d, por um período de seis meses, com acompanhamento por outros seis meses após a suspensão da talidomida. Foram avaliados 42 pacientes multibacilares (MB), 39 (92,85%) da forma virchoviana (V) e três (7,15%) da dimorfa (D), que apresentaram ENH, quer fosse o primeiro episódio ou de repetição. Quanto ao sexo 33 (78,6%) do masculino e nove (21,4%) do feminino. As idades variaram de 18 a 84 anos, com predomínio acima de 49 anos. Observou-se que 100% dos pacientes não apresentaram episódio reacional durante o uso dessa dose de talidomida. Após a suspensão, durante o período de observação clinica, 33 (78,6%) dos pacientes não apresentaram episódio reacional e apenas nove (21,4%), todos da forma virchoviana, o apresentaram, de forma leve, sem outros sinais e sintomas, controlados apenas com anti-inflamatórios não hormonais, não sendo necessária a reintrodução da talidomida. Não foram observados efeitos adversos da droga...
Hansens disease is a chronic disease that can have its course interrupted by reactional episodes of type 1 and type 2 or ENL. Thalidomide is the election medication for the control of ENL episodes since 1965. However, these episodes can happen repeatedly with consequent damages to the patient. In order to avoid these episodes, after controlling them with the traditional dosage, an extra dose of 100mg/d was used in a period of six months, with attendance during other six months after suspending thalidomide. A total of 42 MB patients have been evaluated, 39 (92,85%) of type V and 3 (7,15%) of type D, that presented ENL, whether first episode or repeatedly. To mention their gender, 33 (78,6%) were male and 9 (21,4%) were female. The ages varied between 18 to 84 years old, but most were older then 49. It has been observed that 100% of patients did not present reactional episode during the usage of this dosage of thalidomide. After supension, during the period of clinic observation, 33 (78,6%) patients did not present reactional episode and only 9 (21,4%) patients, both with lepromatous type, presented it, in a light form, with no other signs and symptoms, controlled only with non hormonal anti-iflammatories, showing no need for thalidomide reintroduction. No adverse effect has been observed...
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Erythema Nodosum , Leprosy/diagnosis , Leprosy/drug therapy , Leprostatic Agents/administration & dosage , Leprostatic Agents/therapeutic use , Thalidomide/administration & dosage , Thalidomide/therapeutic useABSTRACT
INTRODUÇÃO: Em 1997, após a realização de estudo multicêntrico, duplo cego e randomizado, em nove centros de tratamento de hanseníase na Índia, o Ministério da Saúde adotou o esquema alternativo dose única ROM para casos de lesão única, paucibacilar, sem nervo periférico afetado, índice baciloscópico negativo, em Centros de Referência da doença no Brasil. O estudo se propôs a avaliar a efetividade do esquema ROM em pacientes tratados no período de 1997 a 1999 no Serviço de Dermatologia da Santa Casa de Vitória. MÉTODOS: Foram selecionados e tratados com o esquema ROM, 54 pacientes das formas indeterminada e tuberculóide. Estes pacientes foram convocados de março a outubro de 2006 para reavaliação clínica. RESULTADOS: Vinte e nove pacientes avaliados (85,2 por cento; IC95 por cento: 70-100,4) estavam curados, cinco (14,7 por cento; IC95 por cento: 7,4-22,0) recidivaram e 20 pacientes não retornaram; porém, não havia outra notificação de reingresso ao tratamento no banco de dados da Secretaria Estadual de Saúde. CONCLUSÕES: O estudo evidenciou taxa de cura de 90,8 por cento e taxa bruta de recidiva de 9,2 por cento, após período de sete a nove anos da dose ROM. O tratamento alternativo ROM demonstrou melhor efetividade para lesão única menor que quatro centímetros e aparecimento há menos de cinco anos.
INTRODUCTION: In 1997, after obtaining a combined multi-state double-blind randomly controlled clinical trial study from nine Indian centers involved in the treatment of Hansen's Disease, the Ministry of Health adapted the single dose ROM Therapy approach in those cases involving the treatment of a single skin lesion, paucibacillary leprosy without evidence of peripheral nerve trunk involvement and indication of negative baciloscope, in the Referral Centers in Brazil. The study aimed to evaluate the effectiveness of the single dose ROM Therapy approach in those patients who were treated from the period of 1997 to 1999 in the Ambulatory Dermatologic Unit in the Hospital in Vitória, ES. METHODS: Fifty-four patients with tuberculoid and indeterminate leprosy were selected and treated with the single dose ROM Therapy approach. These patients were contacted from March 2006 up and until October 2006 for further clinical reevaluation. RESULTS: From the studies conducted, the following results were found to exist: 29 patients (85,2 percent; 95 percentCI: 70-100,4) were cured, 5 patients (14,7 percent; 95 percentCI: 7,4-22,0) relapsed, and 20 patients didn't return; however, there are no additional records of any notification of other treatment(s) in the State Department of Health's informational data banks. CONCLUSIONS: The study demonstrated a rate of cure of 90.8 percent and a rate of relapse of 9.2 percent after a period of seven to nine years using the single dose ROM Therapy approach. Additionally, this alternative treatment further demonstrated a better effectiveness for a single skin lesion smaller than four centimeters and with an appearance in less than five years.
Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Leprostatic Agents/administration & dosage , Leprosy/drug therapy , Minocycline/administration & dosage , Ofloxacin/administration & dosage , Rifampin/administration & dosage , Double-Blind Method , Drug Administration Schedule , Drug Therapy, Combination/methods , Longitudinal Studies , Leprosy, Tuberculoid/drug therapy , Leprosy, Tuberculoid/pathology , Leprosy/pathology , Recurrence , Time Factors , Treatment OutcomeABSTRACT
The objective of this work was to determine the methemoglobinemia and correlate with dapsone levels in multibacillary leprosy patients under leprosy multi-drug therapy. Thirty patients with laboratory and clinical diagnosis of multibacillary leprosy were enrolled. Dapsone was analyzed by high performance liquid chromatography and methemoglobinemia by spectrophotometry. The mean dapsone concentrations in male was 1.42 g/mL and in female was 2.42 g/mL. The mean methemoglobin levels in male was 3.09 µg/mL; 191 percent, and in female was 2.84 ± 1.67 percent. No correlations were seen between dapsone levels and methemoglobin in male and female patients. Our results demonstrated that the dosage of dapsone in leprosy treatment does not promote a significant methemoglobinemia.
Subject(s)
Adolescent , Adult , Female , Humans , Male , Young Adult , Dapsone/blood , Leprostatic Agents/administration & dosage , Leprosy, Multibacillary/drug therapy , Methemoglobinemia/diagnosis , Chromatography, High Pressure Liquid , Clofazimine/administration & dosage , Dapsone/administration & dosage , Dapsone/adverse effects , Leprostatic Agents/adverse effects , Leprosy, Multibacillary/blood , Methemoglobinemia/chemically induced , Rifampin/administration & dosage , Spectrophotometry , Young AdultABSTRACT
The suitability of IgM antibodies to PGL-1 for monitoring the response to multidrug therapy (MDT) was sequentially tested by ELISA in 105 leprosy patients, and bacterial indexes (BI) were also determined. Patients were divided into 3 groups: group 1, 34 multibacillary (MB) patients treated for 12 months with MDT-MB; group 2, 33 MB patients treated for 24 months with MDT-MB, and group 3, 38 paucibacillary (PB) patients treated for 6 months with MDT-PB. Untreated MB patients exhibited higher antibody levels (mean ± SEM): group 1 (6.95 ± 1.35) and group 2 (12.53 ± 2.02) than untreated PB patients (1.28 ± 0.35). There was a significant difference (P < 0.01) in anti-PGL-1 levels in group 1 patients: untreated (6.95 ± 1.35) and treated for 12 months (2.78 ± 0.69) and in group 2 patients: untreated (12.53 ± 2.02) and treated for 24 months (2.62 ± 0.79). There was no significant difference between untreated (1.28 ± 0.35) and treated (0.62 ± 0.12) PB patients. Antibody levels correlated with BI. The correlation coefficient (Pearsons r) was 0.72 before and 0.23 (P < 0.05) after treatment in group 1 and 0.67 before and 0.96 (P < 0.05) after treatment in group 2. BI was significantly reduced (P < 0.01) after 12 and 24 months on MDT (group 1: 1.26-0.26; group 2: 1.66-0.36). Our data indicate that monitoring anti-PGL-1 levels during MDT may be a sensitive tool for evaluating treatment efficacy. These data also indicate that the control of leprosy infection can be obtained with 12 months of MDT in MB patients.
Subject(s)
Humans , Antigens, Bacterial/immunology , Glycolipids/immunology , Immunoglobulin M/blood , Leprostatic Agents/administration & dosage , Leprosy/drug therapy , Mycobacterium leprae/immunology , Drug Administration Schedule , Enzyme-Linked Immunosorbent Assay , Leprosy/immunologyABSTRACT
Claritromicina e clofazimina têm sido utilizadas no tratamento da hanseníase, tuberculose e infecções causadas pelo complexo Mycobacterium avium. Como os dados sobre a toxicidade de esquemas terapêuticos que incluem estes fármacos são escassos, este estudo teve como objetivo determinar os efeitos adversos destas terapias, por meio da avaliação dos parâmetros hematológicos, hemostáticos e bioquímicos. Os fármacos foram administrados em ratos machos Wistar, em monoterapia, em regime de doses única e múltipla. Claritromicina provocou aumento de leucócitos mono e polimorfonucleares. Ambos os fármacos inverteram a proporção entre células mono e polimorfonucleares e provocaram aumento do número de células polimorfonucleares e células em degeneração. Clofazimina e claritromicina prolongaram o tempo de protrombina e claritromicina também prolongou o tempo de tromboplastina parcial ativa. Claritromicina causou aumento de bilirrubinas total e direta e, ambos os fármacos, elevaram os níveis plasmáticos de gama-glutamiltransferase. Portanto, clofazimina e claritromicina induzem alterações hematológicas, hemostáticas e hepáticas.
Clarithromycin and clofazimine have been used to treat leprosy, tuberculosis and infections caused by the Mycobacterium avium complex. Since there is a scarcity of data on the toxicity of therapeutic regimens that include these drugs, this study had the aim of determining the adverse effects of these therapies, through evaluation of hematological, hemostatic and biochemical parameters. The drugs were administered to male Wistar rats, as monotherapy, in regimens of single and multiple doses. Clarithromycin caused increases in the numbers of mononuclear and polymorphonuclear leukocytes. Both of the drugs inverted the proportions between mononuclear and polymorphonuclear cells and increased the numbers of polymorphonuclear cells and degenerating cells. Clofazimine and clarithromycin prolonged the prothrombin time and clarithromycin also prolonged the activated partial thromboplastin time. Clarithromycin caused increases in total and direct bilirubin. Both of the drugs increased the plasma levels of gamma-glutamyltransferase. Therefore, clofazimine and clarithromycin induce hematological, hemostatic and hepatic changes.
Subject(s)
Animals , Male , Rats , Blood Cell Count , Blood Coagulation/drug effects , Clarithromycin/pharmacology , Clofazimine/pharmacology , Leprostatic Agents/pharmacology , Transaminases/drug effects , Clarithromycin/administration & dosage , Clofazimine/administration & dosage , Leprostatic Agents/administration & dosage , Rats, WistarABSTRACT
Multidrug therapy (MDT), with rifampicin, dapsone, and clofazimine, treats leprosy infection but is insufficient in arresting or preventing the nerve damage that causes impairments and disabilities. This case-series study evaluates the benefits of the combined use of steroids and MDT in preventing nerve damage in patients with pure neural leprosy (PNL). In addition to MDT, 24 patients (88 percent male aged 20-79 years, median=41) received a daily morning dose of 60 mg prednisone (PDN) that was gradually reduced by 10 mg during each of the following 5 months. PNL was clinically diagnosed and confirmed by nerve histopathology or PCR. A low prevalence (8.3 percent) of reaction was observed after release from treatment. However, most of the clinical parameters showed significant improvement; and a reduction of nerve conduction block was observed in 42 percent of the patients. The administration of full-dose PDN improved the clinical and electrophysiological condition of the PNL patients, contributing to the prevention of further neurological damage.
A poliquimioterapia (PQT), com rifampicina, dapsona, e clofazimina, trata a infecção na hanseníase, mas é insuficiente para interromper ou prevenir o comprometimento neurológico que causa as incapacidades e desabilidades, nesta enfermidade. Este estudo de série de casos avalia o benefício do uso combinado de prednisona e PQT na prevenção do dano neurológico em pacientes com a forma neural pura da hanseníase (FNP). Além do PQT, 24 pacientes (88 por cento homens, com idade variando entre 20-79, mediana=41) receberam uma dose diária de 60 mg prednisona que foi reduzida gradualmente na dose de 10 mg durante cada um dos 5 meses subseqüentes. FNP foi diagnosticada clinicamente e confirmada através do estudo histopatológico ou PCR. Baixa prevalência de reação (8,3 por cento) foi observada apenas após o final do tratamento. A maioria dos parâmetros clínicos mostrou melhora significativa e redução do bloqueio de condução foi observada em 42 por cento dos pacientes. A administração de doses altas de prednisona melhora a evolução clínica e eletrofisiológica de pacientes com a FNP de hanseníase, contribuindo na prevenção de novos comprometimentos neurológicos.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Glucocorticoids/administration & dosage , Leprostatic Agents/administration & dosage , Leprosy, Tuberculoid/drug therapy , Peripheral Nervous System Diseases/prevention & control , Prednisone/administration & dosage , Clofazimine/administration & dosage , Drug Therapy, Combination , Dapsone/administration & dosage , Electrophysiology , Follow-Up Studies , Longitudinal Studies , Prospective Studies , Rifampin/administration & dosage , Treatment OutcomeABSTRACT
O episódio reacional tipo 1 ou reação reversa é ocorrência inflamatória aguda que atinge a pele e nervos periféricos, encontrada em até 30 por cento dos pacientes com hanseníase, sendo causa comum de incapacidade física. Fatores de risco associados incluem uso de poliquimioterapia e infecções virais. Neste estudo, foram avaliados 620 pacientes com hanseníase. Reação reversa foi diagnosticada em 121 (19,5 por cento) casos, sendo mais freqüente nos indivíduos borderlines (48 por cento). Início da poliquimioterapia foi considerado fator de risco para reação reversa, com 52 por cento dos casos apresentando o primeiro episódio neste momento. Neurite foi documentada em 73 por cento dos casos. A presença de vírus B ou C da hepatite foi documentada em 9 por cento de 55 pacientes com reação reversa e em nenhum dos 57 pacientes sem reação (p = 0, 026; teste exato de Fisher), sugerindo possível papel destes agentes como fatores de risco para desenvolvimento de reação reversa na hanseníase.
Type 1 reaction or reversal reaction is an acute inflammatory episode in the skin and peripheral nerves that is found in up to 30 percent of leprosy patients and commonly causes physical disabilities. Multidrug chemotherapy and viral infections are associated risk factors. In this study, 620 leprosy patients were evaluated. Reversal reactions were diagnosed in 121 cases (19.5 percent) and were most frequently found in borderline patients (48 percent). Starting on multidrug chemotherapy was considered to be a risk factor for reversal reaction: 52 percent of the cases presented their first episode at this time. Neuritis was found in 73 percent of the cases. The presence of hepatitis B or C virus was documented in 9 percent of the 55 patients with reversal reaction, while it was not detected in any of the 57 patients without reaction (p = 0.026, Fishers exact test). This suggests that these agents may have a role as risk factors for developing reversal reactions.
Subject(s)
Adult , Female , Humans , Male , Acute-Phase Reaction/etiology , Hepatitis B/complications , Hepatitis C/complications , Leprostatic Agents/administration & dosage , Leprosy/complications , Acute-Phase Reaction/diagnosis , Case-Control Studies , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Leprostatic Agents/adverse effects , Leprosy/drug therapy , Retrospective Studies , Risk FactorsABSTRACT
OBJECTIVE: To assess risk factors for retreatment of leprosy patients. METHODS: A case-control study with patients from two reference care units in Recife, northeastern Brazil, in 2003. The case group included retreated patients (N=155) and the control group comprised those patients who were not retreated (N=155) matched by year of diagnosis and health care unit. Univariate and multivariate analyses were conducted to test the associations and odds ratios and related 95 percent confidence intervals were estimated. RESULTS: The following factors were found to be significantly associated (p<0.05) with retreatment: occurrence of adverse immunological reactions after treatment completion (OR=2.3; 95 percent CI=1.18;4.83), final bacterial index > 1 (OR=6.43; 95 percent CI=1.67;24.74), therapeutic regimen consisting of sulfone monotherapy (OR=10; 95 percent CI=0.01;0.78) and reports of household contacts (OR=2.2; 95 percent CI=0.24;0.85). CONCLUSIONS: The study findings reinforce that the use of dapsone monotherapy should be discontinued, and highlight the need for epidemiological monitoring of specific groups of leprosy patients after treatment completion through periodical clinical and laboratory evaluation. Further studies to explore the association between final bacterial index and retreatment are strongly recommended.
OBJETIVO: Analisar os fatores de risco para retratamento da hanseníase. MÉTODOS: Estudo de caso-controle com pacientes de duas unidades de referência para tratamento da hanseníase, em Recife, Pernambuco, no de 2003. O grupo de casos incluiu pacientes retratados (N=155) e foi comparado com o grupo controle (N=155), pacientes não retratados pareados por ano-diagnóstico e unidade de saúde. Para testar as associações foram realizadas análises uni e multivariadas, e calculados odds ratios com respectivos intervalos de confiança de 95 por cento. RESULTADOS: Os seguintes fatores apresentaram associação estatisticamente significante (p<0,05) com retratamento: reação hansênica após tratamento (OR=2,3; IC 95 por cento:1,18;4,83); índice baciloscópico final > 1 (OR=6,43; IC 95 por cento:1,67;24,74); tratamento com a monoterapia sulfônica (OR=10; IC 95 por cento: 0,01;0,78); relato de contato intradomiciliar com portadores de hanseníase (OR=2,2; IC 95 por cento:0,24;0,85). CONCLUSÕES: Os resultados reforçam o desuso da monoterapia sulfônica e apontam a necessidade de se monitorizar grupos específicos de pacientes após alta terapêutica, através do acompanhamento clínico e laboratorial periódico. Recomenda-se a realização de novos estudos para explorar a associação entre o índice baciloscópico final e retratamento.
Subject(s)
Leprostatic Agents , Leprostatic Agents/administration & dosage , Leprosy/epidemiology , Leprosy/therapy , Recurrence/prevention & control , Treatment Outcome , Case-Control StudiesABSTRACT
A comparative study was performed on the initial and final bacillary indexes of 213 multibacillary leprosy patients who received 12 doses (Group 1: 128 patients) or 24 doses (Group 2: 85 patients) of multidrug therapy (MDT/WHO) to measure the effectiveness of the two regimens. All patients were evaluated at treatment baseline, 12 months, and 24 months. The reduction in bacillary levels and mean bacillary indexes at 24 months was similar in the two groups. No statistical difference in reaction rates was observed between the two treatment regimens.
Foi realizado um estudo comparativo de dois grupos de pacientes definidos de acordo com o esquema terapêutico, a fim de se avaliarem os índices baciloscópicos: PQT/12 doses (Grupo 1: 128 pacientes) e PQT/24 doses (Grupo 2: 85 pacientes). Todos os pacientes foram avaliados no início do tratamento, aos 12 meses, e novamente aos 24 meses. Ao final dos 24 meses, observou-se uma redução das médias dos índices baciloscópicos, semelhantes nos dois grupos. Não houve diferença estatística na avaliação da freqüência de quadros reacionais nos dois esquemas terapêuticos.